Cryoport, Inc. and the Cell and Gene Therapy Catapult, an independent innovation and technology organization specializing in the advancement of cell and gene therapies, today announced the organizations have entered into a new strategic partnership to support the advancement of cell and gene therapies.
Through this collaboration, Cryoport Systems will establish its first global supply chain logistics center in the U.K., a Good Manufacturing Practice (GMP)-compliant facility located within the bioscience cluster in Stevenage, U.K., at the CGT Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre. The partnership will provide CGT Catapult collaborators, and the larger U.K. cell and gene therapy community, with access to Cryoport’s integrated, end-to-end supply chain capabilities including risk mitigation services and logistics support. The collaboration between the partners will commence operations in early 2024.
“The cell and gene therapy industry has become an area of rapid growth in the U.K. with increasing governmental support, making now the prime opportunity to partner with CGT Catapult to offer advanced therapy manufacturers streamlined solutions for their cold chain logistics needs,” said Jerrell Shelton, CEO of Cryoport. “This partnership provides a valuable step in the expansion of our global supply chain infrastructure buildout to help accelerate the process of clinical development and commercialization of cell and gene therapies in the U.K. It also expands Cryoport Systems footprint and advances our longer-term plans in this region by starting with this initial foothold.”
Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, added, “Cryoport’s expertise in the logistics and supply chain needs of advanced therapy manufacturers is an invaluable addition to the life sciences ecosystem in Stevenage and the wider UK. The services Cryoport offers will support the continued growth of the industry, by strengthening even further the established global supply chains from the UK, and we look forward to the future success of Cryoport in the UK.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!